Skip to content
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Nephrology

Long-Term Monitoring and Prognosis

At a Glance

FRTS1 can affect kidney function gradually, but the timeline varies widely. Regular blood and urine tests, blood-pressure checks, bone and mineral monitoring, medication review, and coordinated nephrology care help identify changes early and protect long-term health.

Because Fanconi Renotubular Syndrome 1 (FRTS1) is a lifelong genetic condition, the focus of care shifts over time from “fixing” immediate problems like childhood rickets to “protecting” kidney function for the decades ahead. Understanding the long-term outlook and the importance of consistent monitoring can help you or your child live well with this rare diagnosis.

The Long-Term Outlook for Kidney Health

Research into FRTS1 is still growing, but we know that the “mitochondrial clumping” caused by the GATM mutation can sometimes lead to slow, progressive kidney damage [1][2].

  • Understanding the Statistics: A study combining data from a small, selected cohort of families estimated a “median kidney survival” (the age by which half of patients in that specific group developed advanced kidney failure) of approximately 51.9 years [3].
  • High Variability: It is vital to remember that this number is an estimate for a small cohort, not a destiny or a prediction of your personal timeline. Some patients have required advanced kidney care in their 30s, while others in the same families have preserved their kidney function well into their 60s [4][5][6].

Because the condition can vary so much—even between a parent and child—your medical team will focus on your specific creatinine and eGFR (estimated Glomerular Filtration Rate) trends to determine your unique path [3][7]. If kidney function does decline, your team will help coordinate referrals for advanced CKD care; it is a reason to plan, not panic.

Lifelong Monitoring Requirements

To catch changes early, you will need a “baseline” of regular, individualized checks. This isn’t just about the kidneys; it’s about the whole body’s mineral balance.

Kidney and Metabolic Checks

  • eGFR and CKD Staging: Routine blood tests to track the stage of Chronic Kidney Disease (CKD) [3][8].
  • Protein and Glucose Leaks: Monitoring how much “trash” (like low-molecular-weight proteins) the kidneys are letting into the urine, which can signal tubule stress [3][9].
  • Blood Pressure: High blood pressure can speed up kidney decline, so keeping it in a healthy range is a priority [10].
  • Medication Safety: Avoid nephrotoxic medicines (like NSAID pain relievers) unless approved by your nephrologist.

Bone and Mineral Checks

  • Bone Density and Alignment: Monitoring for osteomalacia (softening of the bones) in adults or the return of rickets in children [6][11].
  • Lab “Markers”: Regular checks of Alkaline Phosphatase, PTH (parathyroid hormone), and Vitamin D levels to ensure your supplements are working [12][11].
  • Imaging: Occasional kidney ultrasounds to check for nephrocalcinosis (calcium deposits) or stones caused by your medications [13][11].

Living with a Genetic Tubulopathy

The practical side of “survivorship” involves more than just labs; it involves the daily reality of managing a chronic condition.

  • The Pill Burden: Taking multiple doses of phosphate, potassium, or alkali every day can be exhausting. Some patients report that the taste or stomach upset from these minerals makes it hard to stay consistent [14][15]. If this is a struggle, talk to your doctor about prolonged-release versions or different formulations that might be easier to tolerate [16][17].
  • Chronic Fatigue: Many patients with tubular disorders experience persistent tiredness. Because fatigue is nonspecific, discuss it with your doctor so they can assess you for treatable causes like anemia, CKD, electrolyte abnormalities, medication side effects, or sleep disruptions from nighttime urination (nocturia) [18][19].
  • Transitioning Care: One of the most critical times for a patient is the move from pediatric to adult medicine. This should be a planned process that starts in the mid-teens, ensuring the new adult nephrologist has a full “medical passport” of your GATM history [20][21].

By staying engaged with a multidisciplinary team—including nephrologists, geneticists, and sometimes nutritionists or physical therapists—you can manage the risks and focus on long-term quality of life [20][22].

Common questions in this guide

What is the long-term kidney outlook for FRTS1?
Kidney function can decline slowly in some people with FRTS1, but the timing varies widely, even within the same family. In a small, selected group, half of participants developed advanced kidney failure by about age 51.9, but this does not predict an individual timeline; your creatinine and eGFR trends are more useful for personal planning.
What tests are used to monitor FRTS1 over time?
Follow-up is individualized but commonly includes blood tests for creatinine and eGFR, an estimate of how well the kidneys filter blood, urine tests for protein and glucose leakage, and blood-pressure checks. These results help the care team track kidney function and identify changes early.
What bone and mineral checks are needed with FRTS1?
Monitoring may include bone health or bone-density assessment and blood levels of alkaline phosphatase, parathyroid hormone (PTH), and vitamin D. Occasional kidney ultrasound may be used to look for nephrocalcinosis, or calcium deposits, and kidney stones.
Why might someone with FRTS1 feel tired?
Persistent fatigue can have several treatable causes, including anemia, chronic kidney disease, electrolyte abnormalities, medication effects, or sleep disruption from nocturia, which means waking to urinate. Tell your clinician about changes in energy so they can look for the cause rather than assuming fatigue is unavoidable.
How can I make FRTS1 medicines easier to take every day?
Phosphate, potassium, and alkali treatments may require several doses and can cause taste or stomach problems for some people. Ask your care team whether doses can be combined or whether a prolonged-release or different formulation is appropriate, and do not change the schedule on your own.
How should a child with FRTS1 transition to adult kidney care?
Transition should be planned in the mid-teen years rather than left until the last appointment with a pediatric team. A medical summary or passport should include the GATM history and key medical information so an adult nephrologist familiar with rare tubular disorders can continue care safely.

Get notified when new evidence is published on Fanconi renotubular syndrome 1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (22)
  1. 1

    Complex phenotype in Fanconi renotubular syndrome type 1: Hypophosphatemic rickets as the predominant presentation.

    Li CY, Sun Y, Guo WC, et al.

    Clinica chimica acta; international journal of clinical chemistry 2024; (561()):119812 doi:10.1016/j.cca.2024.119812.

    PMID: 38876250
  2. 2

    Glycine Amidinotransferase (GATM), Renal Fanconi Syndrome, and Kidney Failure.

    Reichold M, Klootwijk ED, Reinders J, et al.

    Journal of the American Society of Nephrology : JASN 2018; (29(7)):1849-1858 doi:10.1681/ASN.2017111179.

    PMID: 29654216
  3. 3

    Genetic Screening of Patients With Inherited Fanconi Syndrome.

    Inoki Y, Sakakibara N, Yamamoto A, et al.

    Kidney international reports 2026; (11(7)):106576 doi:10.1016/j.ekir.2026.106576.

    PMID: 42282999
  4. 4

    Association of Familial Fanconi Syndrome with a Novel GATM Variant.

    Kudo H, Suzuki R, Kondo A, et al.

    The Tohoku journal of experimental medicine 2023; (260(4)):337-340 doi:10.1620/tjem.2023.J046.

    PMID: 37286521
  5. 5

    A novel variant in GATM causes idiopathic renal Fanconi syndrome and predicts progression to end-stage kidney disease.

    Seaby EG, Turner S, Bunyan DJ, et al.

    Clinical genetics 2023; (103(2)):214-218 doi:10.1111/cge.14235.

    PMID: 36148635
  6. 6

    Inherited Fanconi renotubular syndromes: unveiling the intricacies of hypophosphatemic rickets/osteomalacia.

    Ragate DC, Memon SS, Karlekar M, et al.

    Journal of bone and mineral metabolism 2024; (42(2)):155-165 doi:10.1007/s00774-023-01490-3.

    PMID: 38310177
  7. 7

    Adherence to Chronic Kidney Disease Screening Guidelines Among Patients With Type 2 Diabetes in a US Administrative Claims Database.

    Folkerts K, Petruski-Ivleva N, Comerford E, et al.

    Mayo Clinic proceedings 2021; (96(4)):975-986 doi:10.1016/j.mayocp.2020.07.037.

    PMID: 33722396
  8. 8

    Obesity and Chronic Kidney Disease in US Adults With Type 1 and Type 2 Diabetes Mellitus.

    Wallace AS, Chang AR, Shin JI, et al.

    The Journal of clinical endocrinology and metabolism 2022; (107(5)):1247-1256 doi:10.1210/clinem/dgab927.

    PMID: 35080610
  9. 9

    Phenotypic Spectrum of HNF4α-Associated Fanconi Renotubular Syndrome.

    Emma F, Böckenhauer D, Mallett AJ, et al.

    Kidney international reports 2026; (11(8)):106616 doi:10.1016/j.ekir.2026.106616.

    PMID: 42440446
  10. 10

    Related factors for kidney disease and high chronic kidney disease progression risk in adult-onset type 1 diabetes mellitus patients from China: a multi-center cross-sectional study.

    Jiang J, Huang W, Lan L, et al.

    Renal failure 2025; (47(1)):2483389 doi:10.1080/0886022X.2025.2483389.

    PMID: 40159884
  11. 11

    Rickets guidance: part II-management.

    Haffner D, Leifheit-Nestler M, Grund A, Schnabel D

    Pediatric nephrology (Berlin, Germany) 2022; (37(10)):2289-2302 doi:10.1007/s00467-022-05505-5.

    PMID: 35352187
  12. 12

    Management of bone disease in cystinosis: Statement from an international conference.

    Hohenfellner K, Rauch F, Ariceta G, et al.

    Journal of inherited metabolic disease 2019; (42(5)):1019-1029 doi:10.1002/jimd.12134.

    PMID: 31177550
  13. 13

    Skeletal Consequences of Nephropathic Cystinosis.

    Florenzano P, Ferreira C, Nesterova G, et al.

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2018; (33(10)):1870-1880 doi:10.1002/jbmr.3522.

    PMID: 29905968
  14. 14

    Recent Developments in the Treatment of Pediatric Distal Renal Tubular Acidosis.

    Boyer O, Ould Rabah M, Preka E

    Paediatric drugs 2024; (26(6)):649-657 doi:10.1007/s40272-024-00651-9.

    PMID: 39325135
  15. 15

    Magnesium lactate in the treatment of Gitelman syndrome: patient-reported outcomes.

    Robinson CM, Karet Frankl FE

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2017; (32(3)):508-512 doi:10.1093/ndt/gfw019.

    PMID: 26940126
  16. 16

    Safety, efficacy, and acceptability of ADV7103 during 24 months of treatment: an open-label study in pediatric and adult patients with distal renal tubular acidosis.

    Bertholet-Thomas A, Guittet C, Manso-Silván MA, et al.

    Pediatric nephrology (Berlin, Germany) 2021; (36(7)):1765-1774 doi:10.1007/s00467-020-04873-0.

    PMID: 33635379
  17. 17

    6-year treatment follow-up with an extended-release alkaline formulation (Sibnayal®) in primary distal renal tubular acidosis.

    Bertholet-Thomas A, De Mul A, Bernardor J, et al.

    Orphanet journal of rare diseases 2025; (20(1)):431 doi:10.1186/s13023-025-03953-4.

    PMID: 40804680
  18. 18

    Management of severe polyuria in idiopathic Fanconi syndrome.

    Filler G, Geda R, Salerno F, et al.

    Pediatric nephrology (Berlin, Germany) 2021; (36(11)):3621-3626 doi:10.1007/s00467-021-05213-6.

    PMID: 34427794
  19. 19

    Muscle and Bone Impairment in Infantile Nephropathic Cystinosis: New Concepts.

    Haffner D, Leifheit-Nestler M, Alioli C, Bacchetta J

    Cells 2022; (11(1)) doi:10.3390/cells11010170.

    PMID: 35011732
  20. 20

    Clinical practice recommendations for the diagnosis and management of nephropathic cystinosis.

    Hohenfellner K, Wühl E, Haffner D, et al.

    Nature reviews. Nephrology 2026; (22(9)):651-670 doi:10.1038/s41581-026-01089-7.

    PMID: 42298212
  21. 21

    Long-term complications of primary distal renal tubular acidosis.

    Santos F, Gil-Peña H

    Pediatric nephrology (Berlin, Germany) 2023; (38(3)):635-642 doi:10.1007/s00467-022-05546-w.

    PMID: 35543873
  22. 22

    Multidisciplinary and multidimensional approaches to transplantation in children with rare genetic kidney diseases.

    George RP, Winterberg PD, Garro R

    Pediatric transplantation 2023; (27(8)):e14567 doi:10.1111/petr.14567.

    PMID: 37522570

This page offers general information about long-term monitoring and prognosis in Fanconi renotubular syndrome 1 for educational purposes only; it does not constitute medical advice. Your nephrologist and care team should interpret your kidney, bone, and mineral results and set your follow-up plan.